Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pulmicort pMDI HFA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pulmicort pMDI |
| 2 | EXPERIMENTAL | Budesonide pMDI |
| 3 | EXPERIMENTAL | Budesonide pMDI + Aerochamber Zero-stat spacer |
| 4 | EXPERIMENTAL | Pulmicort repulses via Spira Nebuliser |
| 5 | EXPERIMENTAL | Pulmicort Turbohaler |
| Name | Type | Description |
|---|---|---|
| Pulmicort pMDI HFA | DRUG | Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
| Budesonide pMDI HFA | DRUG | Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
| Pulmicort Repulses | DRUG | Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations |
| Pulmicort Turbohaler | DRUG | Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * BMI between 18 and 30 kg/m2 * Non-smokers/non-snuffers Exclusion Criteria: * Pregnant and/or lactating women * Use of oral contraceptives or hormonal implants * Known or suspected hypersensitivity to gluc...
Pulmicort pMDI HFA is an investigational small molecule being studied in healthy volunteers. It is a pressurized metered-dose inhaler formulation of budesonide, a corticosteroid. The drug is being evaluated for lung deposition characteristics, though it is not approved for any specific indication and remains in clinical development.
Pulmicort pMDI HFA is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research on this inhaled formulation to assess its deposition in the lungs.
Pulmicort pMDI HFA is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still being studied for its safety and deposition profile in healthy volunteers.
Pulmicort pMDI HFA has one completed Phase 1 clinical trial registered under NCT00975754, titled "Lung Deposition Via Different Inhalation Devices." The study enrolled 16 healthy volunteers in Sweden, with participants aged 18 years and older. The trial was controlled but not double-blinded.
Pulmicort pMDI HFA is a specific pressurized metered-dose inhaler formulation of budesonide, the active ingredient in the Pulmicort brand. The "pMDI HFA" designation refers to the delivery device and propellant used. It is being studied for lung deposition in healthy volunteers.